Feed RLMD
RL

Relmada Therapeutics, Inc.

RLMD · NASDAQ

$4.16 +1.59% (+$0.07)
1M -9.17%
Market Cap $436.3M
P/E Ratio -
Div. Yield -
ROE 47.52%

Bulios Fair Price

$2.25

45.9% downside

Trenutna cena

$4.16

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica RLMD trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
2/9
Valuation
85 /100
Cheap
P/B 2.11x
EV/FFO N/A
P/S N/A
Growth
0 /100
Declining
Book val. growth 14.91%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A
Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor
ROE 47.52%
ROA 28.27%
Asset turnover 0.00x
Debt
100 /100
Low
Current ratio 29.52x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
67 /100
Stable
EPS volatility 13.47%
Profitable years 0
Beta 0.45x

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o RLMD
Online

O podjetju

Relmada Therapeutics, Inc. (RLMD) is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of central nervous system disorders and other neurologically focused health conditions. Their research and development programs are aimed at discovering and developing new drug therapies for mood disorders, pain, and other neurological diseases. Among their main products are drugs based on new pharmacological mechanisms, which have the potential to provide new therapeutic options for patients with these health conditions. Relmada Therapeutics, Inc. aims to bring innovative treatment approaches and improve the quality of life for patients suffering from neurological disorders.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Sergio Traversa

Employees

17

Headquarters

Coral Gables

Prihajajoči dogodki

12 NOV.

Earnings

Upcoming earnings report

51d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.